Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Stacy L. Moulder"'
Autor:
Peng Wei, Wei T. Yang, Lumarie Santiago, Marion E. Scoggins, Rosalind P. Candelaria, Alastair M. Thompson, Gary J. Whitman, Beatriz E. Adrada, Tanya W. Moseley, Jason B White, Vicente Valero, Stacy L. Moulder, Elizabeth Ravenberg, Jennifer K. Litton, Gaiane M. Rauch
Publikováno v:
Cancer
BACKGROUND Heterogeneity exists in the response of triple-negative breast cancer (TNBC) to standard anthracycline (AC)/taxane-based neoadjuvant systemic therapy (NAST), with 40% to 50% of patients having a pathologic complete response (pCR) to therap
Autor:
Julie Lemieux, Michael Gnant, Amylou C. Dueck, Georg Pfeiler, Meritxell Bellet-Ezquerra, Antonio C. Wolff, Magdalena Schwarz, Marcus Vetter, Angela DeMichele, Kathy D. Miller, Kathy Puyana Theall, Miguel Gil-Gil, Hannes Fohler, Patrick G. Morris, Maria Koehler, Stacy L. Moulder, Matthew Bidwell Goetz, Manuel Ruiz-Borrego, Arlene Chan, Aleix Prat, G. Rubovszky, Silvia Antolin Novoa, Otto Metzger Filho, Miguel Martín, Debora Fumagalli, Erica L. Mayer, D. Lu, Fernando Henao, Christian Fesl, Eric P. Winer, Florian Fitzal, Alistair Ring, Tiffany A. Traina, Carter Dufrane, Harold J. Burstein, Sibylle Loibl, Nicholas Zdenkowski, Daniel Egle, Hope S. Rugo, Cynthia Huang Bartlett, Daniel G. Anderson, Eleftherios P. Mamounas, Alan P. Lyss, Zbigniew Nowecki
Publikováno v:
The Lancet. Oncology
Summary Background Palbociclib added to endocrine therapy improves progression-free survival in hormone-receptor-positive, HER2-negative, metastatic breast cancer. The PALLAS trial aimed to investigate whether the addition of 2 years of palbociclib t
Autor:
Emi Sei, Stephen Y. Lai, Shanshan Bai, Nicholas Navin, Alexander Davis, Fang Wang, Aislyn Schalck, Ken Chen, Tapsi Kumar, Ying C. Henderson, Min Hu, Ruli Gao, Yiyun Lin, Yun Yan, Stacy L. Moulder, Simona F. Shaitelman, Jennifer Wang
Publikováno v:
Nature biotechnology
Single-cell transcriptomic analysis is widely used to study human tumors. However, it remains challenging to distinguish normal cell types in the tumor microenvironment from malignant cells and to resolve clonal substructure within the tumor. To addr
Autor:
Lei Huo, Gaiane M. Rauch, Alyson Clayborn, Tanbin Rahman, Pamela McCarthy, David Ramirez, Elizabeth Ravenberg, Sadia Saleem, Stacy L. Moulder, Clinton Yam, W. Fraser Symmans, Jason B White, James Stec, Sausan Abouharb, Bora Lim, Jennifer K. Litton, Senthil Damodaran, Meghan Sri Karuturi, Ryan Sun
Publikováno v:
Investigational New Drugs. 39:509-515
Folate receptor alpha (FRα) has been reported to be expressed in up to 80% of triple-negative breast cancers (TNBC) with limited expression in normal tissues, making it a promising therapeutic target. Mirvetuximab soravtansine (mirvetuximab-s) is an
Autor:
Jessica W.T. Leung, Rosalind P. Candelaria, Jong Bum Son, Elsa Arribas, Peng Wei, Hagar S. Mahmoud, Jingfei Ma, Marion E. Scoggins, Kenneth R. Hess, Jennifer K. Litton, Abeer H Abdelhafez, Stacy L. Moulder, Vicente Valero, Elizabeth Ravenberg, Alastair M. Thompson, Gary J. Whitman, Huong T. Le-Petross, Beatriz E. Adrada, Tanya W. Moseley, Mark D. Pagel, Gaiane M. Rauch, Deanna L. Lane, Benjamin C. Musall, Ken Pin Hwang, Jason B White, Lumarie Santiago, Wei T. Yang
Publikováno v:
Breast Cancer Res Treat
PURPOSE: To determine if tumor necrosis by pretreatment breast MRI and its quantitative imaging characteristics are associated with response to NAST in TNBC. METHODS: This retrospective study included 85 TNBC patients (mean age 51.8 ± 13 years) with
Autor:
Helen Piwnica-Worms, Jennifer K. Litton, Banu Arun, Beatriz E. Adrada, Haven R. Garber, Gaiane M. Rauch, Debu Tripathy, Senthil Damodaran, Elizabeth A. Mittendorf, Vicente Valero, Rashmi Krishna Murthy, Fraser Symmans, Stacy L. Moulder, Lei Huo, Alastair M. Thompson, Naoto T. Ueno, Nuhad K. Ibrahim, Rosalind P. Candelaria, Bora Lim
Publikováno v:
Cancer Research. 80:P2-16
BACKGROUND: Current treatment for early stage triple negative breast cancer (TNBC) includes neoadjuvant systemic chemotherapy (NAST), which is used to assess disease biology and the need for adjuvant treatment in case of residual disease at the time
Autor:
Funda Meric-Bernstam, Rosalind P. Candelaria, Jennifer K. Litton, Gaiane M. Rauch, Beatriz E. Adrada, Colleen T. Eppig, Debu Tripathy, Kenneth R. Hess, Senthil Damodaran, Stacy L. Moulder, Bora Lim, Krzysztof J. Grzegorzewski, Ignacio I. Wistuba, Jason B White
Publikováno v:
Cancer Research. 80:OT2-06
Background:While TNBC patients with pathologic complete response (pCR) or residual cancer burden (RCB-I) have good survival rates, those with extensive residual disease (RCB-II or RCB-III) after neoadjuvant chemotherapy (NACT) have poor prognosis. Pa
Autor:
Abenaa M. Brewster, Rashmi Krishna Murthy, Alastair M. Thompson, Nuhad K. Ibrahim, Vicente Valero, Sarah M. DeSnyder, Senthil Damodaran, Helen Piwnica-Worms, Stacy L. Moulder, Gary J. Whitman, Thorunn Helgason, Jennifer K. Litton, Beatriz E. Adrada, Jill Schwartz-Gomez, Kenneth R. Hess, Carlos H. Barcenas, Banu Arun, Elizabeth A. Mittendorf, Marion E. Scoggins
Publikováno v:
J Clin Oncol
PURPOSE Talazoparib has demonstrated efficacy in patients with BRCA-positive metastatic breast cancer. This study evaluated the pathologic response of talazoparib alone for 6 months in patients with a known germline BRCA pathogenic variant (g BRCA-po
Autor:
Gordon Broderick, Eileen H. Shinn, Bryan Fellman, Ainslee Johnson, Elizabeth Wieland, William Fraser Symmans, Stacy L. Moulder
Publikováno v:
JCO Clinical Cancer Informatics
PURPOSE Nearly 40% of patients with breast cancer discontinue their adjuvant oral endocrine treatment (ET). We measured discontinuation rates of ET at a comprehensive cancer center. We then used an iterative approach to model patterns of determinants
Autor:
Meghan Sri Karuturi, Tara Sanft, Denise A. Yardley, Angela DeMichele, Sibel Blau, Sara A. Hurvitz, Hope S. Rugo, Amy S. Clark, Amelia Zelnak, Aditya Bardia, Das Purkayastha, Cynthia X. Ma, Lowell L. Hart, Stacy L. Moulder
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 27, iss 15
Purpose: Standard-of-care treatment for metastatic hormone receptor–positive (HR+), HER2-negative (HER2−) breast cancer includes endocrine therapy (ET) combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i). Optimal treatment after progr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07d10c70a51cc377dfe2b31a20be89ec
https://escholarship.org/uc/item/0mj128b0
https://escholarship.org/uc/item/0mj128b0